重组人血清白蛋白对嘌呤霉素氨基核苷诱导的肾病大鼠腹水的影响。

Effects of recombinant human serum albumin on ascites in rats with puromycin aminonucleoside-induced nephropathy.

Tsukada M, Shintome M, Matsui T, Tsuchiyama H, Maruyama T, Yuki T, Hanada S, Nakamura N

Central Research Laboratory, The Green Cross Corporation, Hirakata, Osaka, Japan.

Gen Pharmacol. 1998 Aug;31(2):209-14. doi: 10.1016/s0306-3623(98)00002-0.

Abstract

Recombinant human serum albumin (rHSA) (1 g/kg) significantly decreased the weight of ascites in rats with puromycin aminonucleoside-induced nephropathy. 2. Furosemide (1-30 mg/kg) did not significantly reduce the weight of ascites in this model. 3. A combination of rHSA (1 g/kg) with furosemide (5 mg/kg) significantly decreased the weight of ascites in this model compared with furosemide alone. 4. In consideration of these results, rHSA can be a substitute for human serum albumin products prepared from human plasma in therapy for ascites or edema in furosemide-resistant nephrotic syndrome.

摘要

重组人血清白蛋白（rHSA）（1克/千克）显著降低了嘌呤霉素氨基核苷诱导的肾病大鼠的腹水重量。2. 呋塞米（1 - 30毫克/千克）在此模型中未显著降低腹水重量。3. 与单独使用呋塞米相比，rHSA（1克/千克）与呋塞米（5毫克/千克）联合使用显著降低了该模型中的腹水重量。4. 考虑到这些结果，rHSA可替代从人血浆制备的人血清白蛋白产品，用于治疗对呋塞米耐药的肾病综合征中的腹水或水肿。